DE19715594A1 - Analgesic combination - Google Patents

Analgesic combination

Info

Publication number
DE19715594A1
DE19715594A1 DE19715594A DE19715594A DE19715594A1 DE 19715594 A1 DE19715594 A1 DE 19715594A1 DE 19715594 A DE19715594 A DE 19715594A DE 19715594 A DE19715594 A DE 19715594A DE 19715594 A1 DE19715594 A1 DE 19715594A1
Authority
DE
Germany
Prior art keywords
minutes
active ingredient
action
hours
fixed combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19715594A
Other languages
German (de)
Inventor
Dieter Dr Neuser
Monika Dr Fierus
Wolfgang Dr Wiehl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE19715594A priority Critical patent/DE19715594A1/en
Priority to YUP-529/99A priority patent/RS49620B/en
Priority to BR9808875-0A priority patent/BR9808875A/en
Priority to DE59810166T priority patent/DE59810166D1/en
Priority to PCT/EP1998/001926 priority patent/WO1998046235A1/en
Priority to NZ500262A priority patent/NZ500262A/en
Priority to HU0003636A priority patent/HU225601B1/en
Priority to PL336154A priority patent/PL190863B1/en
Priority to JP54342398A priority patent/JP2002503221A/en
Priority to AT98921419T priority patent/ATE253919T1/en
Priority to CA002285979A priority patent/CA2285979C/en
Priority to CNB988041928A priority patent/CN1177589C/en
Priority to RU99124179/15A priority patent/RU2218180C2/en
Priority to EP98921419A priority patent/EP0979087B1/en
Priority to TR1999/02396T priority patent/TR199902396T2/en
Priority to AU74286/98A priority patent/AU742622B2/en
Priority to PT98921419T priority patent/PT979087E/en
Priority to YU52999A priority patent/YU52999A/en
Priority to KR10-1999-7009433A priority patent/KR100532647B1/en
Priority to DK98921419T priority patent/DK0979087T3/en
Priority to US09/402,737 priority patent/US6929805B2/en
Priority to ES98921419T priority patent/ES2210754T3/en
Priority to ARP980101703A priority patent/AR012417A1/en
Publication of DE19715594A1 publication Critical patent/DE19715594A1/en
Priority to NO19994663A priority patent/NO323022B1/en
Priority to HK00106647A priority patent/HK1027505A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to orally applicable pharmaceutical preparations containing a fixed combination of at least one locally quick acting analgesic and at least one systematically long-acting analgesic.

Description

Die vorliegende Erfindung betrifft oral applizierbare Arzneizubereitungen enthaltend eine fixe Kombination von mindestens einem lokal wirkenden Analgetikum mit schnellem Wirkungseintritt und mindestens einem systemisch wirkenden Analgetikum mit langanhaltender Wirkung.The present invention relates to orally administrable pharmaceutical preparations containing a fixed combination of at least one locally acting analgesic rapid onset of action and at least one systemic analgesic with a long-lasting effect.

Es sind bereits lokal wirkende Analgetika mit schnellem Wirkungseintritt bekannt, die z. B. in Form von Sprays oder Lutschtabletten angewendet werden können. Solche Lokalanästhetika zeigen ihre Wirkung bereits nach weniger als einer Minute, besitzen aber nur eine kurze Wirkungsdauer, so daß häufig nachmediziert werden muß, was eine Beeinträchtigung der Sicherheit und der "patienten compliance" bedeutet.Local analgesics with a rapid onset of action are already known e.g. B. in the form of sprays or lozenges. Such Local anesthetics show their effect after less than a minute but only a short duration of action, so that often what must be post-medicated an impairment of safety and "patient compliance" means.

Als besonders interessante lokal wirkende Analgetika seien z. B. die Benzocaine genannt. Sie hemmen die Reizbildung und -leitung in Nerven durch die Blockierung des Natriumstroms.As particularly interesting locally acting analgesics such. B. the Benzocaine called. They block the formation and conduction of stimuli in nerves of sodium current.

Systemisch wirkende Analgetika wie z. B. NSAIDS, insbesondere Acetylsalicylsäure (ASS) stellen eine andere gebräuchliche Möglichkeit zur Schmerzlinderung dar. Mit diesen Analgetika wird die Empfindlichkeit der Nocizeptoren herabgesetzt und die Schmerzlinderung ist durch die Hemmung der Prostaglandinsynthese zu erklären. Bei den meisten dieser systemisch wirkendenden Analgetika wird die maximale Wirksam­ keit erst nach ca. 1-2 Stunden erreicht.Systemic analgesics such as B. NSAIDS, especially acetylsalicylic acid (ASS) are another common way to relieve pain These analgesics reduce the sensitivity of the nociceptors and the Pain relief can be explained by the inhibition of prostaglandin synthesis. At most of these systemic analgesics are maximal effective reached after about 1-2 hours.

Aufgabe der vorliegenden Erfindung ist die Befriedigung des seit langem bestehenden Bedürfnisses eine oral applizierbare Zubereitung anzubieten, welche in einfacher und sicherer Weise eine sofortige analgetische Wirkung mit einer langanhaltenden Wir­ kung verbindet.The object of the present invention is to satisfy the long-standing Need to offer an orally applicable preparation, which is simple and surely an immediate analgesic effect with a long lasting we kung connects.

Als lokal wirkende Analgetika (Element A) können alle Wirkstoffe verwendet werden die einen signifikanten Wirkungseintritt in einem Zeitraum von bis zu 10 Minuten, bevorzugt von 4 Minuten, insbesondere von 1 Minute und ganz besonders von 30 Sekunden zeigen. All active substances can be used as locally acting analgesics (element A) which have a significant onset of action in a period of up to 10 minutes, preferably 4 minutes, in particular 1 minute and very particularly 30 Show seconds.  

Die lokal wirkenden Analgetika (Kombinationselement A) werden zweckmäßiger­ weise in Mengen von 0,5 bis 100 mg, vorzugsweise 1 bis 60 mg und insbesondere 2 bis 30 mg pro einzelner Applikationsform eingesetzt.The locally acting analgesics (combination element A) are more appropriate wise in amounts of 0.5 to 100 mg, preferably 1 to 60 mg and in particular 2 up to 30 mg per single application form.

Die erfindungsgemäße Kombination kann ein oder mehrere Lokalanästhetika als Element A enthalten, z. B. 1, 2 oder 3. Von besonderem Interesse sind Kombinationen mit nur einer Verbindung des Elements A.The combination according to the invention can be one or more local anesthetics Contain element A, e.g. B. 1, 2 or 3. Combinations are of particular interest with only one connection of element A.

Die Wirkstoffe gemäß Element A sind weitgehend bekannt. Als besonders geeignet seien beispielhaft genannt, esterartige Lokalanästhetika wie Benzocain, Amethocain, Amylocain, Butacain, Butoxycain, Butyl, Aminobenzoat, Chloroprocain, Clormecain, Cyclomethycain, Isobutamben, Meprylcain, Oxybuprocain, Procain, Propipocain, Proxymetacain, Tricain etc. Ebenso seien anilid-artige Lokalanästhetika wie Lidocain, Bupivacain, Butanilicain, Carticain, Cinchocain, Clibucain, Etidocain, Mepivacain, Oxethazain, Prilocain, Ropivacain, Ethyl p-piperidinoacetyl-aminobenzoat, Tolycain, Trimecain, Vadocain etc.The active ingredients according to element A are largely known. As particularly suitable Examples include ester-like local anesthetics such as benzocaine, amethocaine, Amylocaine, butacaine, butoxycaine, butyl, aminobenzoate, chloroprocain, clormecain, Cyclomethycaine, isobutambene, meprylcaine, oxybuprocaine, procaine, propipocaine, Proxymetacaine, tricaine etc. Likewise, anilide-like local anesthetics such as lidocaine, Bupivacaine, Butanilicain, Carticaine, Cinchocaine, Clibucain, Etidocaine, Mepivacaine, Oxethazain, prilocaine, ropivacaine, ethyl p-piperidinoacetyl aminobenzoate, tolycaine, Trimecain, Vadocain etc.

Auch sonstige Lokalanästhetika wie z. B. Pramoxin oder ätherische Öle wie Menthol oder Eucalyptus-Öl sind einsetzbar.Other local anesthetics such as B. pramoxin or essential oils such as menthol or eucalyptus oil can be used.

Die als Element B einsetzbaren systemisch wirkenden Analgetika sind ebenfalls weitgehend bekannt. Vorzugsweise seien nicht steroidale entzündungshemmende Mittel (NSAIDs) genannt wie z. B. Phenylessigsäure-Derivate wie Aceclofenac, Alclofenac, Bromfenac, Diclofenac, Fenclofenac etc., Arylessigsäure-Derivate wie Acemetacin, Amfenac, Sodium, Bendazac, Glucametacin, Oxametacin etc., Para-Amino­ phenol-Derivate wie Acetanilid etc., Propionsäure-Derivate wie Alminoprofen, Ibuprofen, Ketoprofen, Flurbiprofen, Naproxen, Oxaprozin, Salicylsäure-Derivate wie Acetylsalicylsäure (ASS), Aluminium-ASS und andere Salze, Diflunisal. Etersalat, Fosfosal, Salol, Salsalat, Salacetamid etc., Pyrazolon-Derivate wie Amidopyrine, Dipyrone etc., Oxicame-Derivate wie Droxicam, Isoxicam, Piroxicam etc., Phenyl­ butazone-Derivate wie Azapropazone, Bumadizone Calcium, Oxyphenbutazon etc., Pyrano-indolessigsäure-Derivate wie Etodolac etc., Anthranilsäure-Derivate wie Glafenin, Na-Meciofenamat, Metenamisäure, Morniflumat etc., Indol-Derivate wie Indomethacin etc., Paracetamol und Paracetamol-Derivate und sonstige NSAIDs wie Anirolac, Benzpiperylon, Benzydamin, Hydrochlond, Na-Butibufen, Chlorthenoxazin, Cinmetacin, Clonixin, Cloracetadol, Difenpiramid, Diproqualon, Etenzamid, Fampro­ fazon, Flupirtin, Maleat, Ibuproxam, Indoprofen, Isamfazon, Meloxicam, Metiazin­ säure, Metifenazon, Nifenazon, Niflumsäure, Mimesulid, Pirazoloc, Pranoprofen, Proquazon, Protizinsäure, Ramifenazon etc.The systemic analgesics that can be used as element B are also largely known. Preferably non-steroidal anti-inflammatory Means (NSAIDs) such as B. phenylacetic acid derivatives such as aceclofenac, Alclofenac, Bromfenac, Diclofenac, Fenclofenac etc., arylacetic acid derivatives such as Acemetacin, Amfenac, Sodium, Bendazac, Glucametacin, Oxametacin etc., para-amino phenol derivatives such as acetanilide etc., propionic acid derivatives such as alminoprofen, Ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozine, salicylic acid derivatives such as Acetylsalicylic acid (ASA), aluminum ASA and other salts, diflunisal. Eater salad, Fosfosal, salol, salsalate, salacetamide etc., pyrazolone derivatives such as amidopyrines, Dipyrones etc., oxicame derivatives such as doxicam, isoxicam, piroxicam etc., phenyl butazone derivatives such as azapropazone, bumadizone calcium, oxyphenbutazone etc., Pyrano-indole acetic acid derivatives such as Etodolac etc., anthranilic acid derivatives such as  Glafenin, sodium meciofenamate, metenamic acid, morniflumate etc., indole derivatives such as Indomethacin etc., paracetamol and paracetamol derivatives and other NSAIDs such as Anirolac, Benzpiperylon, Benzydamin, Hydrochlond, Na-Butibufen, Chlorthenoxazin, Cinmetacin, Clonixin, Cloracetadol, Difpiramid, Diproqualon, Etenzamid, Fampro fazon, flupirtine, maleate, ibuproxam, indoprofen, isamfazone, meloxicam, metiazine acid, metifenazone, nifenazone, niflumic acid, mimesulide, pirazoloc, pranoprofen, Proquazon, Protizinsäure, Ramifenazon etc.

Die systemisch wirkenden Analgetika des Elementes B werden erfindungsgemäß eingesetzt in Mengen von 5 bis 1500 mg, vorzugsweise 8 bis 1000 mg, insbesondere 10 bis 800 mg pro Darreichungsform.The systemic analgesics of element B are according to the invention used in amounts of 5 to 1500 mg, preferably 8 to 1000 mg, in particular 10 to 800 mg per dosage form.

Als Element A werden vorzugsweise schnell wirkende lokale Analgetika eingesetzt, deren optimale Wirkungsdauer 0,5 bis 120 Minuten, vorzugsweise 2 bis 60 Minuten, insbesondere 5 bis 30 Minuten andauert. Als Element B werden vorzugsweise systemische Analgetika verwendet, deren signifikante Wirkung nach 15 Minuten eintritt und bis zu 24 Stunden dauert, vorzugsweise solche, deren Wirkung nach 20 Minuten eintritt und bis zu 12 Stunden, insbesondere bis zu 8 Stunden dauert.Fast-acting local analgesics are preferably used as element A, whose optimal duration of action is 0.5 to 120 minutes, preferably 2 to 60 minutes, especially lasts 5 to 30 minutes. As element B are preferred systemic analgesics used, their significant effect after 15 minutes occurs and lasts up to 24 hours, preferably those whose effect after 20 minutes occurs and lasts up to 12 hours, especially up to 8 hours.

Von besonderem Interesse sind erfindungsgemäße Kombinationen die als Element A ein esterartiges Lokalanästhetikum, insbesondere Benzocain enthalten und als Ele­ ment B Propionsäure-Derivate oder Salicylsäure-Derivate enthalten, insbesondere ASS.Combinations according to the invention of element A are of particular interest contain an ester-like local anesthetic, especially benzocaine and as Ele B contain propionic acid derivatives or salicylic acid derivatives, in particular ACE.

Bevorzugte systemische Analgetika sind solche die eine Wirkungsdauer von mindestens 3 Stunden besitzen.Preferred systemic analgesics are those that have a duration of action of own at least 3 hours.

Die erfindungsgemäße Kombination ist besonders geeignet zur Behandlung entzünd­ licher und/oder schmerzhafter Erkrankungen des Mundrachenraums, insbesondere zur Behandlung von Pharyngitis, Laryngitis, Tonsilitis, Stomatitis, Gingivitis, unterschied­ licher Ätiologie. Die Verabreichung des erfindungsgemäßen Kombinationspräparates erfolgt zweckmäßigerweise oral. The combination according to the invention is particularly suitable for the treatment of inflammation Licher and / or painful diseases of the pharynx, especially for Treatment of pharyngitis, laryngitis, tonsilitis, stomatitis, gingivitis, different etiology. The administration of the combination preparation according to the invention conveniently takes place orally.  

Die Kombination kann in üblichen Formulierungen eingesetzt werden, wobei das Lokalanästhetikum zuerst freigesetzt werden soll und das systemisch wirkende Analgetikum gegebenenfalls auch in Depotform vorliegen kann. Als Beispiel solcher Zubereitungen seien genannt: Kernmantel-Tabletten, Lutsch-Dragees, Kaugummi, Hart-Karamel mit flüssigem, halbfestem oder festem Kern. Ihre Herstellung erfolgt nach üblichen Methoden unter Verwendung gängiger Hilfsstoffe.The combination can be used in conventional formulations, the Local anesthetic should be released first and the systemic one The analgesic may also be in depot form. As an example of such Preparations may be mentioned: kernel tablets, lozenges, chewing gum, Hard caramel with a liquid, semi-solid or solid core. They are manufactured according to usual methods using common auxiliaries.

BeispieleExamples Beispiel 1example 1

Beispielhaft sei eine Tablette mit folgender Zusammensetzung genannt:
ASS-Kerntablette:
500 mg ASS werden mit 30 mg Ascorbinsäure, 75 ml Saccharose, 47 ml mikro­ kristalline Cellulose, 2 mg Saccharin (550fach) und 6 ml Orangensaft-Aroma zu einer Tablette vom Gesamtgewicht 660 mg gepreßt. Diese Kerntabletten werden mit einem Benzocain enthaltenden Dragiersirup gleichmäßig dragiert, wobei insgesamt ca. 5 mg Benzocain und 602 mg Dragiersirup aufgetragen werden. Die vorstehende Tablette zeigt bereits 2 Minuten nach Einnahme ein deutliche analgetische Wirkung die über einen Zeitraum von mehr als 3 Stunden anhält.A tablet with the following composition may be mentioned as an example:
ASS core tablet:
500 mg of ASA are pressed with 30 mg of ascorbic acid, 75 ml of sucrose, 47 ml of microcrystalline cellulose, 2 mg of saccharin (550x) and 6 ml of orange juice flavor to a tablet with a total weight of 660 mg. These core tablets are coated uniformly with a coating syrup containing benzocaine, a total of about 5 mg of benzocaine and 602 mg coating syrup being applied. The tablet above shows a clear analgesic effect just 2 minutes after ingestion that lasts for more than 3 hours.

Beispiel 2Example 2

In Analogie zu Beispiel 1 wird eine Kerntablette mit 300 mg Naproxen umhüllt mit einem Dragiersirup der 500 mg Lidocain enthält. Diese Kombinationszubereitung zeigt einen Wirkungseintritt nach 2 Minuten und eine Wirkungsdauer von mehr als 6 Stunden.In analogy to example 1, a core tablet is coated with 300 mg of naproxen a coating syrup containing 500 mg lidocaine. This combination preparation shows an onset of action after 2 minutes and an action duration of more than 6 hours.

Claims (4)

1. Oral applizierbare Zubereitung enthaltend eine fixe Kombination von mindestens einem lokal wirkenden Analgetikum mit schnellem Wirkungsein­ tritt (Element A) mit mindestens einem systemisch wirkenden Analgetikum mit langanhaltender Wirkung (Element B).1. Orally administrable preparation containing a fixed combination of at least one locally acting analgesic with rapid action occurs (element A) with at least one systemic analgesic long-lasting effect (element B). 2. Zubereitung gemäß Anspruch 1, dadurch gekennzeichnet, daß als Element A ein Wirkstoff eingesetzt wird, der eine optimale Wirkungsdauer von 0,5 bis 120 Minuten zeigt und als Element B ein Wirkstoff eingesetzt wird, mit einer Wirkung von 15 Minuten bis zu 24 Stunden.2. Preparation according to claim 1, characterized in that as element A an active ingredient is used that has an optimal duration of action of 0.5 to Shows 120 minutes and an active ingredient is used as element B, with a Effect from 15 minutes to 24 hours. 3. Zubereitung gemäß Anspruch 1, dadurch gekennzeichnet, daß die Elemente A und B so ausgewählt werden, daß die fixe Kombination eine Wirkungsdauer von 2 Minuten bis zu 12 Stunden besitzt.3. Preparation according to claim 1, characterized in that the elements A and B are selected so that the fixed combination has a duration of action from 2 minutes to 12 hours. 4. Verfahren zur Herstellung einer Zubereitung gemäß Anspruch 1, dadurch gekennzeichnet, daß man die fixe Kombination eines Wirkstoffes des Elemen­ tes A und eines Wirkstoffes des Elementes B gemeinsam mit üblichen Hilfs- und Trägerstoffen und gegebenenfalls weiteren verträglichen Wirkstoffen in eine geeignete Applikationsform überführt.4. A method for producing a preparation according to claim 1, characterized characterized in that the fixed combination of an active ingredient of the elemen tes A and an active ingredient of element B together with conventional auxiliaries and Carriers and optionally other compatible active ingredients in transferred a suitable form of application.
DE19715594A 1997-04-15 1997-04-15 Analgesic combination Withdrawn DE19715594A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
DE19715594A DE19715594A1 (en) 1997-04-15 1997-04-15 Analgesic combination
EP98921419A EP0979087B1 (en) 1997-04-15 1998-04-02 Analgesic combination
TR1999/02396T TR199902396T2 (en) 1997-04-15 1998-04-02 Analgesic joint.
BR9808875-0A BR9808875A (en) 1997-04-15 1998-04-02 Combination of painkillers
AU74286/98A AU742622B2 (en) 1997-04-15 1998-04-02 Analgesic combination
NZ500262A NZ500262A (en) 1997-04-15 1998-04-02 Pharmaceutical combination comprising a rapidly acting local analgesic and a sustained acting systemic analgesic
HU0003636A HU225601B1 (en) 1997-04-15 1998-04-02 Analgesic combination
PL336154A PL190863B1 (en) 1997-04-15 1998-04-02 Analgesic combination
JP54342398A JP2002503221A (en) 1997-04-15 1998-04-02 Painkiller combinations
AT98921419T ATE253919T1 (en) 1997-04-15 1998-04-02 ANALGESIC COMBINATION
CA002285979A CA2285979C (en) 1997-04-15 1998-04-02 Analgesic combination
CNB988041928A CN1177589C (en) 1997-04-15 1998-04-02 Analgesic combination
RU99124179/15A RU2218180C2 (en) 1997-04-15 1998-04-02 Combination of analgetics
YUP-529/99A RS49620B (en) 1997-04-15 1998-04-02 Analgesic combination
DE59810166T DE59810166D1 (en) 1997-04-15 1998-04-02 ANALGESIC COMBINATION
PCT/EP1998/001926 WO1998046235A1 (en) 1997-04-15 1998-04-02 Analgesic combination
PT98921419T PT979087E (en) 1997-04-15 1998-04-02 ANALGESIC COMBINATION
YU52999A YU52999A (en) 1997-04-15 1998-04-02 Analgesic combination
KR10-1999-7009433A KR100532647B1 (en) 1997-04-15 1998-04-02 Analgesic Combination
DK98921419T DK0979087T3 (en) 1997-04-15 1998-04-02 Analgesics combination
US09/402,737 US6929805B2 (en) 1997-04-15 1998-04-02 Analgesic combination
ES98921419T ES2210754T3 (en) 1997-04-15 1998-04-02 ANALGESIC COMBINATION.
ARP980101703A AR012417A1 (en) 1997-04-15 1998-04-14 PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION AND PROCEDURE FOR ITS PRODUCTION.
NO19994663A NO323022B1 (en) 1997-04-15 1999-09-24 Use of a composition comprising an analgesic combination, oral formulation, and method of preparing the formulation.
HK00106647A HK1027505A1 (en) 1997-04-15 2000-10-19 Analgesic combination.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19715594A DE19715594A1 (en) 1997-04-15 1997-04-15 Analgesic combination

Publications (1)

Publication Number Publication Date
DE19715594A1 true DE19715594A1 (en) 1998-10-22

Family

ID=7826504

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19715594A Withdrawn DE19715594A1 (en) 1997-04-15 1997-04-15 Analgesic combination
DE59810166T Expired - Lifetime DE59810166D1 (en) 1997-04-15 1998-04-02 ANALGESIC COMBINATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59810166T Expired - Lifetime DE59810166D1 (en) 1997-04-15 1998-04-02 ANALGESIC COMBINATION

Country Status (24)

Country Link
US (1) US6929805B2 (en)
EP (1) EP0979087B1 (en)
JP (1) JP2002503221A (en)
KR (1) KR100532647B1 (en)
CN (1) CN1177589C (en)
AR (1) AR012417A1 (en)
AT (1) ATE253919T1 (en)
AU (1) AU742622B2 (en)
BR (1) BR9808875A (en)
CA (1) CA2285979C (en)
DE (2) DE19715594A1 (en)
DK (1) DK0979087T3 (en)
ES (1) ES2210754T3 (en)
HK (1) HK1027505A1 (en)
HU (1) HU225601B1 (en)
NO (1) NO323022B1 (en)
NZ (1) NZ500262A (en)
PL (1) PL190863B1 (en)
PT (1) PT979087E (en)
RS (1) RS49620B (en)
RU (1) RU2218180C2 (en)
TR (1) TR199902396T2 (en)
WO (1) WO1998046235A1 (en)
YU (1) YU52999A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045678A2 (en) * 1999-12-21 2001-06-28 Id Pharma Gmbh Medicament, a method for its production and the use thereof
US6423697B1 (en) * 1999-01-14 2002-07-23 Mark Friedman Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache, facial pain, and cervical-muscle spasm
DE102004040630A1 (en) * 2004-08-21 2006-03-09 Balaban, Romulus, Dr.med. Combination therapy with procaine
WO2009095090A1 (en) 2008-02-01 2009-08-06 BSH Bosch und Siemens Hausgeräte GmbH Housing for the drive of an electrical device, particularly a household appliance

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037814A1 (en) * 1999-11-23 2001-05-31 Robert Gordon University Bilayered buccal tablets comprising nicotine
KR20010069756A (en) * 2001-05-08 2001-07-25 유형선 Method for controlled release of acemetacin in the intestinal tract and more particularly in the colon
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
DE102004001093A1 (en) * 2004-01-05 2005-07-28 Liedtke, Rainer K., Dr. Composition and method of a synergistic topical therapy of neuromuscular pain
EP2120945A1 (en) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamine combination
US8231588B2 (en) * 2008-08-01 2012-07-31 Tian Xia Methods for ameliorating pain and devices for delivering a medicament
US8905980B2 (en) 2008-08-01 2014-12-09 Tian Xia Devices for delivering a medicament and methods for ameliorating pain
US8690839B2 (en) 2008-08-01 2014-04-08 Tian Xia Devices for delivering a medicament and connector for same
US20130049931A1 (en) * 2011-08-25 2013-02-28 Elwha LLC, a limited liability company of the State of Delaware Systems, devices, methods, and admixtures of transponders and food products for indication of food attributes
US9516995B2 (en) 2013-12-17 2016-12-13 Biovision Technologies, Llc Surgical device for performing a sphenopalatine ganglion block procedure
US9694163B2 (en) 2013-12-17 2017-07-04 Biovision Technologies, Llc Surgical device for performing a sphenopalatine ganglion block procedure
US9510743B2 (en) 2013-12-17 2016-12-06 Biovision Technologies, Llc Stabilized surgical device for performing a sphenopalatine ganglion block procedure
US10016580B2 (en) 2013-12-17 2018-07-10 Biovision Technologies, Llc Methods for treating sinus diseases
DE102015114799A1 (en) * 2015-09-04 2017-03-09 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Pressure medium unit, with a plastic housing produced by injection molding and process for its preparation
WO2019064090A1 (en) * 2017-09-28 2019-04-04 Zenvision Pharma Llp Novel pharmaceutical composition comprising mefenamic acid and other analgesic
WO2020005910A1 (en) 2018-06-28 2020-01-02 Sandler Scientific, Llc Sino-nasal rinse delivery device with agitation, flow-control and integrated medication management system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1026501A (en) * 1961-10-13 1966-04-20 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US4446140A (en) * 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
DE3328401A1 (en) 1983-08-05 1985-02-21 Merckle GmbH, 7902 Blaubeuren INJECTABLE SOLUTION FOR TREATING INFLAMMATION
US4851233A (en) * 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
US5064858A (en) 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
DE69014513T2 (en) 1989-09-21 1995-05-24 American Cyanamid Co "Once a day" pulsed minocycline delivery system.
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
IT1242642B (en) 1990-04-17 1994-05-16 Alfa Wassermann Spa INJECTABLE FORMULATIONS CONTAINING NAPROXEN SODIUM SALT.
GB9121204D0 (en) 1991-10-04 1991-11-20 Euro Celtique Sa Medicament
ES2173096T3 (en) 1992-08-05 2002-10-16 Faulding F H & Co Ltd PHARMACEUTICAL COMPOSITION PELETIZED.
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5702723A (en) * 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5547948A (en) 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
JPH11502839A (en) * 1995-03-29 1999-03-09 ザ、プロクター、エンド、ギャンブル、カンパニー Antitussive microcapsules

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423697B1 (en) * 1999-01-14 2002-07-23 Mark Friedman Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache, facial pain, and cervical-muscle spasm
WO2001045678A2 (en) * 1999-12-21 2001-06-28 Id Pharma Gmbh Medicament, a method for its production and the use thereof
WO2001045678A3 (en) * 1999-12-21 2002-04-11 Id Pharma Gmbh Medicament, a method for its production and the use thereof
DE102004040630A1 (en) * 2004-08-21 2006-03-09 Balaban, Romulus, Dr.med. Combination therapy with procaine
WO2009095090A1 (en) 2008-02-01 2009-08-06 BSH Bosch und Siemens Hausgeräte GmbH Housing for the drive of an electrical device, particularly a household appliance

Also Published As

Publication number Publication date
NO994663L (en) 1999-09-24
BR9808875A (en) 2000-07-11
CA2285979A1 (en) 1998-10-22
CN1177589C (en) 2004-12-01
RS49620B (en) 2007-08-03
KR100532647B1 (en) 2005-12-02
HU225601B1 (en) 2007-05-02
AR012417A1 (en) 2000-10-18
HUP0003636A3 (en) 2001-12-28
ES2210754T3 (en) 2004-07-01
DK0979087T3 (en) 2004-03-08
PL190863B1 (en) 2006-02-28
PT979087E (en) 2004-03-31
AU742622B2 (en) 2002-01-10
CA2285979C (en) 2009-11-24
AU7428698A (en) 1998-11-11
HUP0003636A2 (en) 2001-05-28
RU2218180C2 (en) 2003-12-10
US6929805B2 (en) 2005-08-16
JP2002503221A (en) 2002-01-29
HK1027505A1 (en) 2001-01-19
NZ500262A (en) 2002-04-26
CN1252725A (en) 2000-05-10
EP0979087A1 (en) 2000-02-16
EP0979087B1 (en) 2003-11-12
DE59810166D1 (en) 2003-12-18
ATE253919T1 (en) 2003-11-15
NO994663D0 (en) 1999-09-24
WO1998046235A1 (en) 1998-10-22
PL336154A1 (en) 2000-06-05
NO323022B1 (en) 2006-12-27
YU52999A (en) 2002-06-19
TR199902396T2 (en) 2000-01-21
KR20010006348A (en) 2001-01-26
US20010002999A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
EP0979087B1 (en) Analgesic combination
DE69916922T2 (en) Ibuprofen-containing medicament preparation
EP0607128B2 (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
DE3852481T2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING S (+) IBUPROFEN, WHICH IS MAINLY FREE OF ITS R (-) ANTIPODES.
EP0267321B1 (en) Medicament containing ibuprofen
US5889057A (en) Flurbiprofen lozenge for the treatment of sore throat
DE69004221T2 (en) Solid pharmaceutical preparations containing hydrogenated isomaltulose and an active ingredient.
DE3428729A1 (en) AGENT FOR PREVENTING OR INHIBITING ALVEOLA BONE RESORPTION
DE69309492T2 (en) ANTIPYRETIC AND ANALGETIC COMPOSITIONS CONTAINING OPTICALLY PURE R-KETOROLAC
WO2001015682A1 (en) Pharmaceutical tramadol salts
DE3627423A1 (en) MEDICINAL PRODUCTS CONTAINING DIPYRIDAMOL OR MOPIDAMOL AND O-ACETYLSALICYL ACID OR THEIR PHYSIOLOGICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING THROMBUS FORMATION
EP0250648B1 (en) Pharmaceutical preparation for the sustained release of ibuprofen
DE3603576A1 (en) USE OF TANNING SUBSTANCES AND / OR CHLOROIC ACID AND FOOD, ENJOYMENT AND / OR MEDICINAL PRODUCTS WITH ADDITIVES OF TANNING AGENT AND / OR CHLOROGENIC ACID
DE69817379T2 (en) PHARMACEUTICAL PREPARATIONS CONTAINING IBUPROFEN AND DOMPERIDON FOR TREATING MIGRAINE
DE4319438C1 (en) Analgesic and/or antiinflammatory medicaments - contg. sepd enantiomers of ketoprofen
CN1195510C (en) Semisolid pharmaceutical formulation containing dexketoprofen trometamol
CH667592A5 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 9,10-DIHYDROGENATED ERGOTAL CALOIDS.
JPH02500189A (en) Treatment of gingivitis with ibuprofen or flurbiprofen
MXPA99009225A (en) Analgesic combination
DE2144584A1 (en) Effervescent preparations for the treatment of heart diseases
DE3836863A1 (en) Liquid, dissolved antirheumatic pharmaceutical preparations
DE2918943A1 (en) Oral zinc medicaments for treatment of zinc disorders - contg. lactose and methylcellulose to reduce gastrointestinal irritation

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee